NRX Pharmaceuticals, Inc.

Big Rock Partners Acquisition Corp. (Nasdaq: BRPA), sponsored by Big Rock Partners LLC, completed its initial public offering in 2017 with a stated focus on identifying acquisition targets in the healthcare and life sciences sectors. The company filed its 10-K annual report with the SEC in March 2019, covering fiscal year 2018, a period during which the blank-check company remained in active search for a qualifying business combination. BRPA ultimately announced a merger with NeuroRx, Inc., the clinical-stage biopharmaceutical company focused on central nervous system and pulmonary treatments that later rebranded as NRX Pharmaceuticals, with the transaction closing in 2021. Sign up at SpacDesk for full filing history, deal timelines, and comparable SPAC transaction data.